Anti-TNF therapy in autoimmune hepatitis: We should move faster

Journal of Hepatology · Published 2026-08-01 · DOI 10.1016/j.jhep.2026.07.027

Authors (5)

Johannes Hartl, Jan Philipp Weltzsch, Marcial Sebode, Christoph Schramm, Ansgar Wilhelm Lohse

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Citation

Hartl, J., Weltzsch, J., Sebode, M., et al. (2026). Anti-TNF therapy in autoimmune hepatitis: We should move faster. Journal of Hepatology. https://doi.org/10.1016/j.jhep.2026.07.027

Related articles

• Moving Too Fast? A Meta-Analysis Calls for Caution on TNF Inhibitors as First-Line Therapy for Autoimmune Hepatitis · Journal of Hepatology · 2026 · Cites or is cited by this article · Same journal
• Quantitative Bias Analysis of Unmeasured Confounding Refines Interpretation of Longitudinal Associations Between Cardiometabolic Risk Factors and Liver Stiffness in MASLD · Journal of Hepatology · 2026 · Same journal
• Updates in clinical science: Alcohol-related hepatitis · Journal of Hepatology · 2026 · Same journal
• Low-dose bevacizumab plus atezolizumab enhances transarterial chemoembolization in HCC via correcting vascular-immune niche dysfunction · Journal of Hepatology · 2026 · Same journal
• OSM-STAT3 signaling facilitates Long-term expansion of Pediatric Hepatic Organoids · Journal of Hepatology · 2026 · Same journal
• JHEP at a glance (August 2026) · Journal of Hepatology · 2026 · Same journal
• Before repurposing Fusobacterium nucleatum in alcohol-associated liver disease: it is a rare, non-resident organism in the human alcoholic gut · Journal of Hepatology · 2026 · Same journal
• Declining but persistent hepatocellular cancer risk beyond 10 years of entecavir or tenofovir in chronic hepatitis B: Results of the PAGE-B cohort · Journal of Hepatology · 2026 · Same journal
• Non-selective β-blockers reduce bacterial translocation by restoring gut barrier function during experimental cirrhosis · Journal of Hepatology · 2026 · Same journal
• Metabolic dysfunction profiles identify heterogeneous hepatocellular carcinoma risk in MASLD-associated advanced fibrosis · Journal of Hepatology · 2026 · Same journal